these cases involved contraindicated drugs. However, to the best of our knowledge, there has been no published epidemiologic study on the use of cisapride with contraindicated drugs and mortality in a population-based setting. A properly designed study was necessary to identify the risk of mortality associated with concomitant use of cisapride and contraindicated drugs.
This study was conducted to estimate the prevalence of the use of cisapride with contraindicated drugs and evaluate the association between this coprescription and the risk of all-cause mortality.
Methods

DATABASE
Korea's Health Insurance Review Agency (HlRA) was established on July 1,2000, to combine claims data review and healthcare assessment, under the responsibility of a single agency independent from insurers, providers, and other interested parties. All Koreans are entitled to be either an employed member or a community member under the national health insurance system. When any beneficiary demonstrates signs and/or symptoms that indicate a need for medical care, the patient is provided with regional medical services and the providers then submit claims to the HIRA for a review of the incurred medical costs. Therefore, the HIRA database contains all information on claims made, as well as on prescriptions.
We obtained a database containing claims data submitted by health providers based in Busan under the condition of confidentiality on patient information. Our study was exempt from review by the institutional review board of Seoul National University Hospital at the time of its planning, because it fell under the remission criteria as a retrospective study using an existing dataset for academic purposes that did not involve personal information. The data were provided after deleting the last digit of each patient's citizen registration number so that the code could be used only for data sorting and linking purposes without revealing the individual identity of each patient. Only authorized researchers had access to the database for analysis.
The city of Busan is 450 kilometers southeast of Seoul, the nation's capital, and is the second largest city in Korea, with a population of 3.81 million as of 2001. The database includes the patients' citizen registration number (without the last digit), age, sex, clinic registration number, diagnosis, and list of prescribed drugs. The information provided on the drugs included brand name, generic name, prescription date, and duration and route of administration. Diagnoses were coded according to the International Classification of Disease, Tenth Revision (ICD-lO).
COHORT
The study population was defined as patients younger than 85 years who visited clinics or hospitals in the Busan metropolitan area between November 1,2000, and April 30,2002, as new users of cisapride. New cisapride users were defined as patients who took cisapride during this period for the first time without a history of having been prescribed the drug during the preceding 3 months.
From nearly 20 million prescriptions with valid records in the database, we identified every prescription of cisapride during the study period. All prescriptions relating to the same patient were identified using the key based on the citizen registration number and were linked together. We extracted information on 55 393 patients and 93 608 relevant prescriptions. We then excluded 18528 patients who did not meet the criteria (18 434 were not new cisapride users and 94 were >85 y of age). The final study cohort included 36865 new cisapride users and 56012 prescriptions.
DRUG EXPOSURE
Coprescription of cisapride was defined as the prescription of cisapride with at least one contraindicated drug on the same prescription. The contraindicated drugs that were considered in the study were based on Notification No.
2004-2 announced by the Korea Ministry of Health and
Welfare (Table 1) . The selection was made based on chemical equivalency regardless of label or package. citizen registration number(withoutthe last digit),cause of death coded according to ICD -10 standards, and date of death. All-cause mortality was defined as any disease-related death, excluding accidental deaths caused by traffic accidents, other external causes of accidental injury, intentional self-harm, and assaults.
IDENTIFICAnON OF DEATH
STATISTICAL ANALYSES
The prevalence of the coprescription of cisapride was estimated as the proportion of co-prescribed patients out of the total numberof new users of cisapride. The association between cisapride coprescription and the risk of mortality was measured by rate ratios (RRs). The RRs with 95% confidence intervals were estimated using Cox's regression model with time-dependent covariate. The point of time for each coprescription was considered in the analysis to accountfor a possibledifference in the risk of deathduring or outside the period of combined use. Consecutive start and end times of co-prescriptions were recorded for each subject to indicate every change in time-dependent exposure over the study period. The model included one time-dependent covariate(exposure) and severalfixed covariates (confounders):
f34X4+~sXs+~A+~,X, Which estimatesthe hazard at time t depending on the value of X, at t and on the values of X 2, X 3, X 4, X s, X6, and X,.XI(t) =1ifon combineduse at time t; 0 otherwise.
The follow-up time for each individual was from the date of the first cisapride prescription until the earliest of the following dates: death, 85th birthday, or December31, 2002.The RRs were adjustedfor age, sex, and comorbidities such as heart, respiratory system,and digestive system disease,as well as neoplasms. Comorbidity data were constructedfrom records of diagnosismade at the time of cisapride prescription.Heart disease, respiratorysystem disease, digestive system disease, and neoplasms were definedaccording to the ICD-10 diagnosis codes.
We performed separate analysis that took into account the time lapse between the time of last combined use and time of death,adjusted for age, sex, and comorbidities. The combined users were classified into 2 categories; recent users (last combineduse within 30 days of death) and past users (beyond30 days). Statistical analysis was performed using the SAS statistical application program(Release 9.1, SAS Institute Inc, Cary,NC).
Results
A total of 36 865 patients were newly prescribed cis-apridebetweenNovember1,2000, and Apri130,2002;the numberof cisapride prescriptions administered to thesepa-IncreasedMortalitywith Coprescription ofCisapride and Contraindicated Drugs tientswas 56012. Among the total cohort,58.8% were female, with a mean ± SO age of 28.5 ± 24.1 years. Among the new cisapride users, 1175 (3.2%) were prescribed at least one contraindicated drug with cisapride,which made up 1635 (2.9%) ofthe total claims. The 3 contraindicated drugs most commonly co-prescribed with cisapride were amitriptyline (486 claims),mequitazine (308), and terfenadine (292;Table2).
There was a significant age difference (p < 0.001) between the groups of cisapride users who were prescribed contraindicated drugs and those who were not. Among the new users of cisapride who did not take contraindicated drugs, 48.6% were 0-24 years old and 9.2% were 65-84 years old. However, 27.5% of the co-prescribed users were 0-24 years old, and 17.9% were 65-84 years old. The proportion of contraindicated drug users did not differ significantly according to sex (p = 0.13) or comorbidities such as respiratory system disease (p =0.86) and neoplasms (p = 0.16). Comorbiddigestive system diseasewas more likely to be found in users who were not prescribed contraindicated drugs (p < 0.001), and heart disease was found more often in those prescribed contraindicated drugs (p = 0.002;Table3).
The frequency with which cisapride was co-prescribed with contraindicated drugs varied throughout different age groups. Patients aged 65-84 years had the highest prevalence of coprescription (6.0%), while the lowest prevalence (1.8%) was for the group aged 0-24 years. Among patients with respiratory system diseases, 3.2% used contraindicated drugs. The prevalence of coprescribing cisapride with contraindicated drugs in those with digestive system disease, heart disease, and neoplasms was 2.5%, 6.1%, and 4.4%, respectively (Table 3 ). The relationship between cisapride coprescription and mortality risk is shown in Table 4 . The total number of deaths was 564. There had been no accidental deaths found. Forty-four patients out of the 564 were co-prescribed cisapride with contraindicated drugs, giving a crude RR of 2.63 (95% CI 1.91 to 3.63). The adjusted RR was 1.73 (95% CI 1.25 to 2.40). The adjusted RRs were 14.08 (95% CI 7.41 to 26.76) for recent cisiapride users and 1.33 (95% CI 0.92 to 1.93) for past users.
Discussion
The results of this retrospective population-based cohort study showed that, despite the discontinuation of the commercial marketing of cisapride by Janssen Pharmaceutica, cisapride was still newly prescribed to 36 865 patients in the Busan area between November 1,2000, and April 30, 2002. We also found that 3.2% of these patients were coprescribed cisapride with contraindicated drugs. The recent coprescription of contraindicated drugs increased the risk of all-cause mortality compared with the prescription of cisapride without contraindicated drugs. However, the risk was not significant after 30 days from the time of last combined use.
We observed that the concomitant users were older and more likely to have heart disease than were those who were not prescribed contraindicated drugs. This might be related to the higher risk of mortality in those prescribed contraindicated drugs. To minimize the possibility of such confounding effects, we adjusted the results for age, sex, and comorbidities; the overall adjusted RR became smaller than the crude RR, but significantly greater than I, suggesting that interaction caused by the use of cisapride with contraindicated drugs might contribute to death. We also conducted a separate analysis based on the indication of heart disease and the result showed that the combined use was still a risk factor in patients who did not have heart disease (adjusted RR 1.74; 95% CI 1.25 to 2.44).
In order to investigate a causal relationship, it is important to know whether the deaths occurred during at-risk periods. In our study, the status of the combined medication use varied with time, and therefore an additional level of complexity was introduced due to the need to account for time-dependent exposure in Cox's regression model.P:"
Time-dependent covariates change in value over the COurse of observation. Subgroup analyses were also performed based on the time lapse between last combined use and death. From the present results, we conclude that there could be a link between the combined use of cisapride with contraindicated drugs and death. Cisapride is metabolized by the CYP3A4 enzyme system, and the concomitant use of drugs that inhibit these enzymes can increase plasma cisapride concentrations and induce QT interval prolongation.P In 1995, therefore, a black box warning was added to the labeling on cisapride Products, stating that certain drugs that inhibit the enzymes Werecontraindicated with cisapride because they could potentially cause fatal arrhythmia; a list of the contraindicated drugs was included with this warning,"
The combined use of cisapride with other medications known to prolong the QT interval could also have additive effects on QT interval." In June 1998, the use of class IA and class ill antiarrhythmic drugs and drugs known to prolong the QT interval, as well as certain medical conditions (ie, history of prolonged QT intervals, ventricular arrhythmia, ischemic heart disease, renal failure, congestive heart failure, respiratory failure, uncorrected electrolyte disorders) Wereadded to the black box warning as contraindications. 9 Several studies have reported the estimated prevalence of coprescribing cisapride with contraindicated drugs. In the US, a retrospective study of prescription claims from a managed-care organization database for all patients with cisapride prescriptions between July 1993 and December 1998 was conducted and published." Of 131485 cisapride prescriptions dispensed after the warnings began, 4414 (3.4%) overlapped with at least 1 contraindicated drug on the labels at the time of the prescription. In the Netherlands, among cisapride users from 1994 to 1998,944 (3.1 %) patients used 1 or more potentially interacting drugs," Compared with these studies, our study focused on a specific period following the removal of cisapride from the market; the results highlighted the fact that cisapride Was co-prescribed with contraindicated drugs after cisapride's market withdrawal in proportions similar to those found in the previous studies.
Although our results were derived from an observational study, the study's strength is in the fact that it was the first population-based study to investigate the association between the coprescription of cisapride with contraindicated drugs and mortality. We studied an entire target population, rather than a sampled one, that was prescribed cisapride in a chosen area during the study period. While several case reportsand postrnarketing safety data have suggested the link between cisapride and QT interval prolongation and torsade des pointes,2.9,lS,l6 they did not evaluate the outcome of coprescribing cisapride with potential interacting drugs.
Increased Monality withCoprescription ojCisaprideand Contraindicated Drugs
When relying on spontaneous reports, it is not practical to estimate population risks because considerable underreporting of adverse events is likely. For example, in the case of arrhythmia, underreporting could be an even more serious factor because sudden cardiac deaths are often reported without documentation of arrhythmia," Our study period was limited to the period following the discontinuation of the commercial marketing of cisapride, which enabled us to observe the impact of the discontinued marketing on the use of the drug and estimate the prevalence of the use of cisapride with contraindicated drugs. We restricted our analysis to new users of cisapride, in order to maintain control of the various underlying conditions of patients as long-term users and of any possible bias in the selection regarding early emergence symptoms, drug intolerance, or treatment failure,"
Our results should also be interpreted with some limitations in mind. Even though we tried to make adjustments to minimize confounding effects, the information on potential confounding factors that we used might not have been complete. For example, we considered diagnoses as reported to HIRA, which might differ from the patients' actual diagnosis. A validation study compared the diagnosis derived from the HIRA database with the actual diagnosis in the patients' medical records." Positive predictive value (PPV) was calculated according to disease groups. The PPV was 77 .6% for neoplasm, 67.4% for stroke, and 58.6% for rheumatoid arthritis. The overall PPV of the diagnoses was 81.8% in the case of inpatients. However, the diagnosis may not provide sufficient information on the severity of individual disease status and medical history. However, because the Korean drug regulatory agency had already warned against the combined use of cisapride and contraindicated drugs through new labels and by distributing prescription guides to physicians, any remaining confounders may have little impact.
We chose mortality as the event of interest. It might have been more reasonable to consider serious ventricular arrhythmia or prolongation of the QT interval as the outcome to evaluate the effect of coprescription in cisapride users. However, one known reason for the failure of previous observational studies I9 • 22 to confirm or refute the association between cisapride and cardiac adverse events was outcome misclassification." The difficulty of accurately diagnosing QT prolongation would have had a significant impact on misclassification. Furthermore, a variety of terms were used for outcomes associated with cardiac toxicity, and it appeared that some relevant outcomes were often not included, thus contributing to the failure of these studies in confirming the hypothesis. Mortality is clearly defined and easily traceable to avoid such classification problems, but it might be questionable for all-cause mortality to be used as an outcome of a direct effect of the coprescription.
wwwsheannalscom
TheAnnalsofPharmacotherapy • 2007April,Volume 41 • 671
Conclusions
We found that, despite the discontinuation of its commercial marketing, cisapride was stillin use through available sources; in many cases,it was co-prescribed withcontraindicated drugs. Our findings also suggested that drug interactions with the contraindicated co-prescribeddrugs mightcontribute to an increase in the risk of mortality. Cisapride has been withdrawn in most major markets, but it is still used via a limited-access protocol. Cisapride shouldbe prescribed to carefully chosen patients and should not be prescribed withcontraindicated drugs.
EXTRACfO TRASFONDO: No se habfapublicado un estudio epidemiol6gico sobre el usa de cisapride concurrentemente con drogas contraindicadasy su relaci6n con tasas de mortalidad en un contexto poblacional. OB,JETIVOS: Estimar la prevalenciadel uso de cisapride concurrentemente con drogas contraindicadasy evaluar la asociaci6n entre la prescripci6n de cisapride concurrentementecon drogas contraindicadasy el riesgo de mortalidad.
MtToDOS: Se obtuvieron datos provenientesde reclamaciones ante la Agencia Revisora del Segura de Salud de Korea. La poblaci6n bajo estudio consisti6 de pacientes menores de 85 aiios de edad que visitaron clfnicasy hospitalesen la ciudad de Busan como usuarios nuevos de cisapride entre el primero de noviembre de 2000 Yel 30 de abril de 2002. La prescripci6nconcurrente de cisapride fue definida como prescribir cisapride con una 0 mas drogas contraindicadasen la misma receta. Tambien se utilizarondatos de morta1idad a nivel nacional. Se estim6 la prevalencia de la prescripci6nconcurrente de cisapride y la asociaci6nentre la prescripci6n de cisapride concurrentementecon drogas contraindicadasy el riesgo de morta1idad, fue evaluado mediante razones de tasas. Lasrazones de tasas fueron estimadas usando el modelo de regresi6n de Cox con variables dependientes del tiernpo, ajustadas por edad, genero y comorbilidades. RESULTADOS: De 56012 reclamaciones, un total de 36865 correspondfan a pacientes que eran usuarios nuevos de cisapride, de los cuales a 1175 pacientes (3.2%) se les prescribi6 por 10menos una droga contraindicadaconcurrentementecon cisapride. Esto sugiri6 una raz6n de tasas de mortalidad ajustacta de 14.08 (IC 95% 7.41 y 26.76) para usuarios recientes y 133 (Ie 95% 0.92 y 1.93)para aquellos que habfan usado la droga en el pasado. CONCLUSIONES: A pesar de que se descontinu6 el mercadeo comercial de la droga, cisapride ann sigue en uso y en muchos casos, es prescrita concurrentemente con drogascontraindicadas. Esta prescripci6n concurrente esta asociada con mortalidad. The 13th edition includes a "do not use" list of dangerous abbreviations in addition to the 28,000 meanings for the abbreviations, acronyms, and symbols. The book also contains a cross-referenced list of 3,400 generic and trade drug names. Each copy includes a single-user access license for the web version of the book which is updated with over 100 new entries per month. This license is valid for 24 months from the date of initial log-in.
Essential to medical professionals for order interpretation, data entry, unit dose cart filling, and prescription interpretation. A must to ensure patient safety and reduce medication errors. 
